Japanese Study Finds Gilenya Limits Lesions and Relapses in MS Patients

0
(0)

A Japanese study has found that long-term use of the drug Gilenya (fingolimod) helps to limit brain lesions and relapses in multiple sclerosis patients.

Gilenya could help treat SPMS by countering astrocytes. Find out more here. 

The three-year study is Phase 2 of a clinical research project following 147 patients with relapsing multiple sclerosis. The initial phase found that fewer detectable lesions were picked up on MRI scans in MS patients taking Gilenya than those who took a different medication (interferon beta-1a) after six months on the drug.

Phase 2 followed the progress of 143 of the original patients on Gilenya after three years and discovered that 88 to 100 percent of patients had no new or enlarged T2 lesions and 75 to 100 percent had no new T1 lesions.

The number of relapses experienced by patients in the trial also dropped, with between 45 percent and 62 percent of patients being relapse-free. Find out more about this study here. 

Switching from Gilenya to Lemtrada seen to trigger disease activity in some MS patients. Read more here.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *